Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With Rituximab in Participants With Selected CD19+ and CD20+ Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

NCT06334991 is registered in ClinicalTrials.gov with ImmunityBio, Inc. as lead sponsor.

NCT NCT06334991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06334991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With Rituximab in Participants With Selected CD19+ and CD20+ Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Lead sponsor
ImmunityBio, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
August 23, 2024
Completion date
October 31, 2027
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma refractory/ relapsed